Plant ID: NPO4702
Plant Latin Name: Trichosanthes rosthornii
Taxonomy Genus: Trichosanthes
Taxonomy Family: Cucurbitaceae
NCBI TaxonomyDB:
676073
Plant-of-the-World-Online:
294288-1
China
ADORA3; ADORA2A; ADORA1; FFAR1; FFAR4; | |
TSHR; NPSR1; | |
ACHE; | |
RECQL; TDP1; ADK; GLO1; ALOX12; HSD17B1; HSD17B10; ALOX15; NOX4; APEX1; POLB; | |
TOP2A; | |
AXL; FLT3; CDK1; PIM1; MET; KDR; IGF1R; AURKB; CSNK2A1; | |
CA12; CA7; CA4; | |
ESR2; | |
MMP12; | |
HIF1A; | |
LMNA; FABP3; FABP4; THPO; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.538E-08 | 5.219E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.009E-07 | 1.196E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 3.835E-07 | 2.037E-04 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 9.175E-07 | 4.343E-04 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.309E-06 | 5.815E-04 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.600E-06 | 6.968E-04 | ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 1.965E-06 | 8.388E-04 | ALOX15, APEX1, AXL, CYP1A1, CYP1B1, FABP4, FFAR4, FLT3, HIF1A, IGF1R, KDR, NOX4, TSHR |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 3.427E-06 | 1.288E-03 | ALOX12, CDK1, CSNK2A1, FLT3, HIF1A, IGF1R, KDR, MMP12, PIM1, THPO, TSHR |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 5.071E-06 | 1.534E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.071E-06 | 1.534E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.923E-06 | 1.534E-03 | CA12, CA4, CA7 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.071E-06 | 1.534E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 5.178E-06 | 1.544E-03 | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1 |
MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 9.773E-06 | 2.533E-03 | ACHE, ADORA1, APEX1, CSNK2A1, FLT3, IGF1R, KDR, L3MBTL1, MMP12, PIM1, TSHR |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.043E-05 | 2.641E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.112E-05 | 2.720E-03 | APEX1, AXL, CDK1, CYP1B1 |
BP | GO:0032502; developmental process | GO:0007568; aging | 1.323E-05 | 3.066E-03 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.425E-05 | 3.220E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.519E-05 | 3.220E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.519E-05 | 3.220E-03 | ALOX12, ALOX15 |
CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.519E-05 | 3.220E-03 | ADORA1, ADORA2A |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.892E-05 | 3.729E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 2.632E-05 | 4.777E-03 | ALOX12, ALOX15, APEX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD17B1, HSD17B10, NOX4 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 2.666E-05 | 4.797E-03 | AXL, CDK1, CSNK2A1, FLT3 |
MF | Unclassified; | GO:0004872; receptor activity | 2.752E-05 | 4.856E-03 | ADORA1, ADORA2A, ADORA3, AXL, ESR2, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, TSHR |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.034E-05 | 5.243E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0005504; fatty acid binding | 3.105E-05 | 5.282E-03 | FABP3, FABP4, FFAR4 |
BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 3.132E-05 | 5.287E-03 | ADORA2A, APEX1, CDK1, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FLT3, NOX4 |
BP | GO:0008152; metabolic process | GO:0016042; lipid catabolic process | 3.189E-05 | 5.342E-03 | ADORA1, CYP19A1, CYP1A2, CYP1B1, FABP3, FABP4 |
BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 4.141E-05 | 6.630E-03 | ALOX12, CA12, CA7, FABP3, FABP4, FFAR1, HIF1A, MET, NOX4, NPSR1 |
BP | GO:0050896; response to stimulus | GO:0010243; response to organonitrogen compound | 4.521E-05 | 7.032E-03 | ADORA2A, APEX1, CDK1, FABP3, FFAR4, FLT3, IGF1R, NOX4, TSHR |
BP | GO:0002376; immune system process | GO:0030097; hemopoiesis | 4.965E-05 | 7.479E-03 | FLT3, HIF1A, KDR, L3MBTL1 |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 5.049E-05 | 7.479E-03 | ALOX12, ALOX15 |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 5.090E-05 | 7.489E-03 | ADORA1, ADORA2A, ADORA3, AXL, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, TSHR |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 5.236E-05 | 7.502E-03 | ACHE, ADORA3, ALOX15, CDK1, CYP1A1 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 5.223E-05 | 7.502E-03 | CSNK2A1, HIF1A, KDR |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 6.283E-05 | 8.659E-03 | AXL, FLT3, IGF1R, KDR, MET |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.471E-05 | 9.859E-03 | CA12, CA4, CA7 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.241E-18 | 4.482E-16 | CA12, CA1, CA3, CA2, CA5A, CA4, CA7, CA6, CA9, CA14 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 4.422E-13 | 4.422E-11 | CAMK2B, SRC, MMP2, PIK3R1, HIF1A, ESR1, MMP9, PTK2, PIK3CG, IGF1R, KDR, AKT1, MAPK1, TP53, MET, TLR2 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.975E-12 | 1.317E-10 | GSK3B, FLT3, DAPK1, MMP2, PIK3R1, PTGS2, HIF1A, MMP9, NFKB1, PIK3CG, PTK2, IGF1R, AR, CDK6, AKT1, MAPK1, PPARG, MET, TP53, PPARD |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.848E-11 | 1.924E-09 | HSD17B1, ALOX5, INSR, HSD17B2, CYP1A1, CYP1B1, PTGS2, CYP19A1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.125E-10 | 4.501E-09 | FABP4, INSR, ADORA1, AKT1, PIK3R1, PTGS2, TSHR, PIK3CG, PTGS1 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.195E-10 | 7.318E-09 | CYP2C9, APP, CYP2C8, MAOA, ALOX5, ALOX15, MAPK1, ALOX12, CYP2C19, PTGS2, PTGS1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 2.914E-10 | 8.325E-09 | CYP2C9, CYP2C8, PLA2G1B, ALOX5, ALOX15, ALOX12, CYP2C19, PTGS2, PTGS1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.059E-09 | 2.102E-08 | GSK3B, SYK, INSR, PIK3R1, PTK2, NFKB1, PIK3CG, IGF1R, CDK6, KDR, AKT1, MAPK1, PKN1, TP53, MET, TLR2 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 5.972E-10 | 1.493E-08 | PKM, FLT3, AKT1, MAPK1, PIK3R1, TP53, MET, HIF1A, PIK3CG |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.156E-09 | 2.102E-08 | GSK3B, SRC, AKT1, MAPK1, PIK3R1, ESR1, NFKB1, ESR2, PIK3CG |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 3.782E-09 | 5.979E-08 | CDK6, SRC, AKT1, MAPK1, STAT6, PIK3R1, TP53, MMP9, NFKB1, PIK3CG, TLR2 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 3.887E-09 | 5.979E-08 | FLT3, PIM1, AKT1, MAPK1, PIK3R1, NFKB1, PIK3CG, PPARD |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 7.849E-09 | 1.047E-07 | GSK3B, AR, AKT1, MAPK1, PIK3R1, TP53, NFKB1, PIK3CG, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 6.774E-09 | 9.677E-08 | SRC, KDR, AKT1, MAPK1, PIK3R1, PTGS2, PTK2, PIK3CG |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.135E-08 | 1.419E-07 | CAMK2B, CDK6, AKT1, MAPK1, PIK3R1, TP53, PIK3CG, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 2.021E-08 | 2.378E-07 | SRC, MMP2, AKT1, MAPK1, PIK3R1, ESR1, MMP9, ESR2, PIK3CG |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 6.777E-10 | 1.506E-08 | CYP2C9, CYP2C8, PLA2G1B, CYP1A2, ALOX15, CYP3A4, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.315E-08 | 2.572E-07 | CDK6, AKT1, MAPK1, PIK3R1, TP53, MET, PIK3CG, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 2.866E-08 | 3.017E-07 | CAMK2B, INSR, AKT1, MAPK1, PIK3R1, HIF1A, NFKB1, PIK3CG, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 4.708E-08 | 4.484E-07 | PTPN1, GSK3B, INSR, AKT1, PIK3R1, PYGL, PPARA, NFKB1, PIK3CG |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 3.367E-08 | 3.367E-07 | HPGD, FLT3, MMP3, PPARG, TP53, MPO, MMP9, MET, NFKB1, PTK2, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 9.407E-08 | 7.416E-07 | CAMK2B, ADORA2A, ADORA1, AKT1, MAPK1, PIK3R1, PPARA, CFTR, NFKB1, TSHR, PIK3CG |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.095E-07 | 7.416E-07 | GSK3B, SYK, CSNK2A1, CDK1, AKT1, CD38, PIK3R1, ITGAL, TP53, NFKB1, PIK3CG |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 9.389E-08 | 7.416E-07 | GSK3B, SRC, AKT1, MAPK1, PIK3R1, TP53, ESR1, HIF1A, PIK3CG |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.095E-07 | 7.416E-07 | GSK3B, SRC, KDR, AKT1, MAPK1, PIK3R1, MET, PTK2, PIK3CG, MYLK, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 8.675E-08 | 7.416E-07 | ALK, CDK6, AKT1, MAPK1, PIK3R1, TP53, PIK3CG |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.272E-07 | 7.948E-07 | POLB, CDK6, PKM, SYK, SRC, CDK1, MAPK1, PIK3R1, TP53, NFKB1, PIK3CG |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.702E-07 | 1.032E-06 | ADORA2A, SRC, INSR, KDR, AKT1, MAPK1, PIK3R1, ITGAL, MET, PIK3CG, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.086E-07 | 7.416E-07 | ABCC1, ADORA3, ADORA1, AKT1, MAPK1, PIK3R1, TP53, NFKB1, PIK3CG |
09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 1.062E-07 | 7.416E-07 | CDK6, AKT1, PIK3R1, PTGS2, TP53, NFKB1, PTK2, PIK3CG |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 7.295E-08 | 6.631E-07 | CYP2C9, CYP2C8, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19, PTGS2 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 1.755E-07 | 1.033E-06 | ADORA3, INSR, ADORA1, AKT1, MAPK1, PIK3R1, ADRA2C, ADRA2A, PIK3CG, MYLK |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 1.163E-07 | 7.504E-07 | CAMK2B, GSK3B, SRC, AKT1, MAPK1, PIK3R1, PTK2, PIK3CG |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 2.131E-07 | 1.218E-06 | INSR, AKT1, PPARG, PIK3R1, TP53, NFKB1, PIK3CG, IGF1R |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 5.579E-07 | 2.656E-06 | PLA2G1B, MAOA, ALOX15, ADK, AKR1B1, ALOX12, PYGL, PTGS2, CYP2C19, CYP3A4, CYP19A1, HSD17B10, PTGS1, HSD17B1, ALOX5, HSD17B2, CD38, XDH, GAA, CYP2C9, CYP2C8, PKM, CYP1A2, ALDH1A1, CYP1A1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 3.178E-07 | 1.673E-06 | GSK3B, CDK6, CSNK2A1, AKT1, PIK3R1, TP53, NFKB1, PIK3CG, TLR2 |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 2.757E-07 | 1.532E-06 | CDK6, AKT1, MAPK1, PIK3R1, TP53, NFKB1, PIK3CG |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 7.176E-07 | 3.262E-06 | MMP3, AKT1, MAPK1, PIK3R1, PTGS2, MMP9, NFKB1, PIK3CG |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 2.907E-06 | 1.211E-05 | PLA2G1B, INSR, KDR, AKT1, MAPK1, PIK3R1, MET, NFKB1, PIK3CG, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.112E-07 | 7.416E-07 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 5.549E-07 | 2.656E-06 | CDK6, AKT1, MAPK1, PIK3R1, TP53, NFKB1, PIK3CG |
09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 1.578E-06 | 6.714E-06 | SYK, SRC, AKT1, MAPK1, PIK3R1, PIK3CG, MYLK, PTGS1 |
09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 5.549E-07 | 2.656E-06 | GSK3B, SYK, AKT1, MAPK1, PIK3R1, NFKB1, PIK3CG |
09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.392E-06 | 6.053E-06 | CAMK2B, GSK3B, AKT1, MAPK1, PIK3R1, TP53, NFKB1, PIK3CG |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 4.427E-06 | 1.703E-05 | PARP1, LMNA, AKT1, MAPK1, PIK3R1, TP53, NFKB1, PIK3CG |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 3.020E-06 | 1.233E-05 | GSK3B, AKT1, MAPK1, PIK3R1, PPARA, TP53, NFKB1, PIK3CG |
09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 4.526E-06 | 1.708E-05 | GSK3B, CXCR1, SRC, AKT1, MAPK1, PIK3R1, NFKB1, PTK2, PIK3CG |
09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 4.197E-06 | 1.646E-05 | PTPN1, GSK3B, INSR, AKT1, MAPK1, PIK3R1, PYGL, PIK3CG |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 6.095E-07 | 2.835E-06 | PTPN1, CSNK2A1, SRC, INSR, MAPK1, MET, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 3.757E-07 | 1.926E-06 | FABP2, FABP3, FABP4, FABP5, PPARG, PPARA, PPARD |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 5.021E-06 | 1.807E-05 | MMP2, PIM1, AKT1, MAPK1, PIK3R1, NFKB1, PIK3CG |
09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 1.079E-05 | 3.722E-05 | CAMK2B, SRC, CD38, MAPK1, PIK3R1, PTGS2, PIK3CG, MYLK |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 3.029E-05 | 9.616E-05 | ABCC1, CDK6, PIM1, CYP1B1, MAPK1, PTGS2, TP53, MMP9, MET, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 1.402E-05 | 4.751E-05 | ALOX5, AKT1, MAPK1, PIK3R1, NFKB1, PIK3CG, TLR2 |
09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 2.901E-05 | 9.358E-05 | SYK, AKT1, MAPK1, PPARG, PIK3R1, NFKB1, PIK3CG |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 1.936E-05 | 6.348E-05 | INSR, AKT1, PPARG, PIK3R1, CFTR, PIK3CG, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 5.062E-05 | 1.534E-04 | SYK, CXCR1, INSR, AKT1, MAPK1, PIK3R1, PIK3CG |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 6.839E-05 | 1.964E-04 | GSK3B, INSR, AKT1, PIK3R1, PPARA, NFKB1, PIK3CG |
09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.223E-06 | 5.436E-06 | GSK3B, AKT1, MAPK1, PIK3R1, TP53, PIK3CG |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 4.926E-05 | 1.516E-04 | CDK1, AKT1, MAPK1, PIK3R1, PIK3CG, IGF1R |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.003E-04 | 2.712E-04 | ADORA2A, GPR35, ADORA3, ADORA1, NMUR2, ADRA2C, ADRA2A, DRD4, TSHR |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.868E-07 | 1.550E-06 | DAPK1, SRC, MMP2, MAPK1, MMP9, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 3.498E-06 | 1.399E-05 | GSK3B, AKT1, MAPK1, PIK3R1, TP53, PIK3CG |
09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 9.875E-05 | 2.705E-04 | CAMK2B, ACHE, AKT1, MAPK1, PIK3R1, PIK3CG |
09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 6.873E-05 | 1.964E-04 | GSK3B, AKT1, MAPK1, PIK3R1, NFKB1, PIK3CG |
09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 7.644E-05 | 2.153E-04 | AKT1, MAPK1, PIK3R1, NFKB1, PIK3CG, TLR2 |
09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 6.873E-05 | 1.964E-04 | AKT1, MAPK1, PIK3R1, NFKB1, PIK3CG, TLR2 |
09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 5.058E-06 | 1.807E-05 | AKT1, MAPK1, PIK3R1, MET, HIF1A, PIK3CG |
09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 3.366E-04 | 8.209E-04 | POLB, GSK3B, AKT1, PIK3R1, ITGAL, TP53, NFKB1, PIK3CG |
09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 1.906E-04 | 4.766E-04 | CAMK2B, SYK, SRC, AKT1, MAPK1, NFKB1, TLR2 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 4.623E-06 | 1.712E-05 | CYP2C9, CYP2C8, CYP1A2, ALDH1A1, CYP1A1, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 6.566E-06 | 2.304E-05 | CYP2C9, CYP2C8, MAOA, CYP1A2, CYP3A4, CYP2C19 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.655E-04 | 6.555E-04 | INSR, AKT1, MAPK1, PIK3R1, PIK3CG, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 3.773E-04 | 9.092E-04 | GSK3B, AKT1, MAPK1, PIK3R1, PIK3CG, IGF1R |
09150 Organismal Systems | 09151 Immune system | hsa04670 | Leukocyte transendothelial migration | 1.384E-04 | 3.594E-04 | MMP2, PIK3R1, ITGAL, MMP9, PTK2, PIK3CG |
09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 5.800E-04 | 1.275E-03 | SRC, MAPK1, PIK3R1, ITGAL, PTK2, PIK3CG, MYLK |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 6.641E-04 | 1.444E-03 | THPO, PIM1, AKT1, STAT6, PIK3R1, PIK3CG |
09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 9.146E-04 | 1.967E-03 | BACE1, APP, GSK3B, MAPK1, MAPT, HSD17B10 |
09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 1.129E-03 | 2.353E-03 | GSK3B, AKT1, MAPK1, PIK3R1, NFKB1, PIK3CG |
09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.993E-04 | 1.148E-03 | CAMK2B, SRC, ALOX12, PIK3R1, PIK3CG |
09150 Organismal Systems | 09152 Endocrine system | hsa04922 | Glucagon signaling pathway | 5.732E-04 | 1.274E-03 | CAMK2B, PKM, AKT1, PYGL, PPARA |
09150 Organismal Systems | 09151 Immune system | hsa04666 | Fc gamma R-mediated phagocytosis | 3.923E-04 | 9.232E-04 | SYK, AKT1, MAPK1, PIK3R1, PIK3CG |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 4.912E-05 | 1.516E-04 | AKT1, MAPK1, PIK3R1, HIF1A, PIK3CG |
09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 5.477E-04 | 1.245E-03 | PIK3R1, NFKB1, PTK2, PIK3CG, TLR2 |
09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 5.732E-04 | 1.274E-03 | AKT1, MAPK1, PIK3R1, HIF1A, PIK3CG |
09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 8.985E-05 | 2.496E-04 | SYK, AKT1, MAPK1, PIK3R1, PIK3CG |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04310 | Wnt signaling pathway | 2.612E-03 | 5.023E-03 | CAMK2B, GSK3B, CSNK2A1, TP53, PPARD |
09150 Organismal Systems | 09153 Circulatory system | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.122E-03 | 5.890E-03 | CAMK2B, AKT1, MAPK1, PIK3R1, PIK3CG |
09150 Organismal Systems | 09151 Immune system | hsa04650 | Natural killer cell mediated cytotoxicity | 2.097E-03 | 4.072E-03 | SYK, MAPK1, PIK3R1, ITGAL, PIK3CG |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 3.923E-04 | 9.232E-04 | SYK, CSNK2A1, PARP1, PTGS2, NFKB1 |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 6.713E-05 | 1.964E-04 | INSR, AKT1, PIK3R1, PIK3CG, IGF1R |
09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 1.392E-03 | 2.812E-03 | CAMK2B, AR, CDK1, MAPK1, IGF1R |
09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 1.718E-03 | 3.369E-03 | CAMK2B, GSK3B, MAOA, AKT1, DRD4 |
09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 1.726E-04 | 4.369E-04 | SRC, PIK3R1, MET, PTK2, PIK3CG |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.261E-04 | 3.362E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 3.196E-03 | 5.974E-03 | CAMK2B, SRC, MMP2, MAPK1 |
09150 Organismal Systems | 09154 Digestive system | hsa04972 | Pancreatic secretion | 3.873E-03 | 7.106E-03 | CA2, PLA2G1B, CD38, CFTR |
09150 Organismal Systems | 09154 Digestive system | hsa04971 | Gastric acid secretion | 1.501E-03 | 2.971E-03 | CAMK2B, CA2, CFTR, MYLK |
09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 1.427E-03 | 2.854E-03 | MAPK1, PTGS2, NFKB1, TLR2 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 1.641E-05 | 5.471E-05 | PKM, INSR, MAPK1, PIK3R1, PIK3CG |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.287E-03 | 2.653E-03 | CA2, CYP3A4, CFTR, ABCG2 |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.095E-03 | 2.306E-03 | CXCR1, SRC, MET, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05144 | Malaria | 4.237E-03 | 7.704E-03 | ITGAL, MET, TLR2 |
09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 1.283E-04 | 3.377E-04 | INSR, MAPK1, PIK3R1, PIK3CG |
09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 3.327E-03 | 6.161E-03 | AKT1, PIK3R1, PIK3CG |
09130 Environmental Information Processing | 09131 Membrane transport | hsa02010 | ABC transporters | 3.120E-03 | 5.890E-03 | ABCC1, CFTR, ABCG2 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.419E-04 | 3.638E-04 | MAOA, CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 9.257E-04 | 1.969E-03 | MAPK1, PPARG, TP53 |
09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 1.356E-03 | 2.767E-03 | POLB, PARP1, APEX1 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 4.332E-04 | 1.007E-03 | CYP1A2, XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; FFAR1; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; HIF1A; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
NA: NA | Hepatitis C virus infection | NA | ADORA3; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; HIF1A; ADORA3; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; CYP19A1; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; ADORA2A; ADK; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ADORA1; ADORA2A; |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA1; ADORA2A; ADORA3; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; ADORA1; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; ADORA2A; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |